Ituxredi (Rituximab)

Rituximab is a monoclonal antibody that binds to the CD20 antigen on B‑lymphocytes. This binding activates complement pathways and recruits immune cells, leading to antibody‑dependent cellular cytotoxicity and programmed cell death. The result is selective depletion of CD20‑expressing B cells, which are central to the pathology of the indicated diseases.

The dosing regimen for Ituxredi is individualized based on the specific indication, patient characteristics, and treatment protocol. The prescribing physician determines the appropriate dose, infusion rate, and schedule. Patients should follow the dosing instructions provided by their healthcare professional and not adjust the regimen on their own.

The safety of rituximab in pregnancy and lactation has not been fully established. It is generally recommended to avoid use unless the potential benefits justify the potential risks to the fetus or infant. Women of childbearing potential should discuss contraception and pregnancy plans with their physician before starting therapy.

To request Ituxredi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details—including cold‑chain logistics—and necessary import documentation.

Rituximab is a biologic therapy that specifically targets CD20‑positive B cells, offering a mechanism distinct from conventional chemotherapy or small‑molecule immunosuppressants. Compared with some alternatives, it provides targeted B‑cell depletion with a different safety profile, often allowing for combination with other agents. Choice of therapy depends on disease stage, patient tolerance, and physician assessment.

Ituxredi must be stored refrigerated at 2‑8 °C. The product should be kept in its original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold chain during transport and handling is essential to preserve product stability and efficacy.

Ituxredi is supplied as an intravenous solution and is administered by a qualified healthcare professional through an IV infusion. The infusion rate and duration are determined by the prescribing physician and may be adjusted based on patient tolerance and the specific treatment protocol.

Serious risks include severe infections, hepatitis B reactivation, progressive multifocal leukoencephalopathy (PML), anaphylaxis, and cardiac arrhythmias. Patients should be monitored closely for signs of infection, liver dysfunction, neurological changes, and allergic reactions throughout treatment and follow‑up periods.

Ituxredi is contraindicated in patients with known hypersensitivity to rituximab or any component of the formulation. It should also be avoided in individuals with active severe infections, uncontrolled cardiac disease, or those who have received live vaccines within four weeks of treatment. Clinical judgment is required for each patient.